🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementWhen to stop GLP-1 — what worked for you?

When to stop GLP-1 — what worked for you?

oliver_london Mon, Nov 11, 2024 at 10:08 PM 14 replies 1,866 viewsPage 1 of 3
This thread is more than 19 months old. Information may be outdated. Consider searching for more recent discussions.
oliver_london
Member
312
1,345
Aug 2024
London, UK
Nov 11, 2024 at 10:08 PM#1

Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

Trial-level incidence runs roughly 20 to 25% for nausea at the higher dose tiers and 12 to 17% for diarrhoea, with most events mild to moderate and concentrated in the weeks after each escalation.

What would genuinely help is knowing what distinguishes the nausea you can titrate through from the nausea that means stop.

Not looking for reassurance. Looking for the part I have got wrong.

10 5Admin, Dr.Martinez, mike_mod and 7 others
Reply Quote Save Share Report
LarryQC_SD
Senior Member
2,123
9,876
Jan 2024
San Diego, CA
Nov 11, 2024 at 10:17 PM#2

Taking the question as asked, rather than the general version of it. The line between titrate-through and stop is not severity, it is trajectory and what else is present. Nausea that peaks and improves within a week is the expected pattern. Nausea that is escalating, or that comes with severe upper-abdominal pain radiating to the back, or that prevents fluids for more than a day, is a different conversation and belongs with a clinician the same day.

9 4paul_denver, TinaHashiRN, robert_kc and 6 others
Reply Quote Save Share Report
jason_sac26
New Member
34
123
Jan 2026
Sacramento, CA
Nov 11, 2024 at 10:26 PM#3
LarryQC_SD said:
The line between titrate-through and stop is not severity, it is trajectory and what else is present.

Agreed on adaptation, with a caveat: adaptation applies to gastric emptying and not to everything. If your problem is the aversion rather than the fullness, waiting does less, because the aversion is central and it is the mechanism working as intended.

Last edited: Nov 12, 2024 at 12:26 AM
8 3stefan_berlin, Dr.EM_Chicago, pete_RVA and 5 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
jennifer_SEA
Member
234
890
Nov 2024
Seattle, WA
Nov 11, 2024 at 10:35 PM#4
oliver_london said:
Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

This matches mine closely enough to be worth saying so. The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the fat fraction of meals in the two days after dosing, and do not lie down straight after eating. Most of what people call unmanageable nausea is a meal-size and meal-composition problem interacting with a stomach that is emptying slowly.

7 2jim_asheville, matt_MKE, Dr.ReproEndo and 4 others
Reply Quote Save Share Report
Dr.SurgeonPGH
Senior Member
1,345
6,789
Mar 2024
Pittsburgh, PA
Nov 11, 2024 at 11:20 PM#5

Adding the clinical framing, because it changes how the question reads. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

6 1B12Beth, RickReta_CO, PharmHunterJen and 3 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register